伊沙佐米为基础的化疗方案治疗复发难治多发性骨髓瘤临床研究  

Clinical study on ixazomib-based chemotherapy regimens in treatment of relapsed/refractory multiple myeloma

作　　者：付彬[1] 谷梨花 刘萍 孙福金 张千惠 关建民 Fu Bin;Gu Lihua;Liu Ping;Sun Fujin;Zhang Qianhui;Guan Jianmin(Department of Hematology,Heze Municipal Hospital of Shandong Province,Heze 274000,China;Department of Hematology,Zoucheng People's Hospital of Shandong Province,Zoucheng 273500,China;Graduate School of Shandong First Medical University,Taian 250000,China)

机构地区：[1]山东省菏泽市立医院血液科,274000 [2]山东省邹城市人民医院血液科,273500 [3]山东第一医科大学研究生院,山东泰安250000

出　　处：《白血病．淋巴瘤》2021年第6期340-343,共4页Journal of Leukemia & Lymphoma

摘　　要：目的探讨以伊沙佐米为基础的化疗方案治疗复发难治多发性骨髓瘤(RRMM)的临床效果及相关不良反应。方法收集2018年10月至2020年2月山东省菏泽市立医院、邹城市人民医院接受≥2个疗程以伊沙佐米为基础化疗方案治疗的RRMM患者21例,其中既往接受过含硼替佐米方案治疗患者15例,接受过含来那度胺方案治疗患者10例,接受过含以上两种药物方案治疗患者6例。采用伊沙佐米(4 mg,口服,第1、8、15天)联合其他药物(地塞米松、环磷酰胺或来那度胺)的两药或三药方案治疗。治疗第2、4个周期后评估其治疗效果及安全性。结果21例RRMM患者治疗2个周期后评估总反应率(ORR)为38.09%(8/21),其中部分缓解(PR)6例、非常好的部分缓解(VGPR)2例;4个周期后ORR为57.14%(12/21),其中PR 7例、VGPR 4例、完全缓解(CR)1例。以伊沙佐米为基础的化疗方案3~4级不良反应发生率为23.81%(5/21),血液学不良反应包括中性粒细胞减少、血小板降低及贫血,其他常见不良反应包括消化道反应、乏力、低钾血症等,周围神经不良反应均为2级及以下。结论以伊沙佐米为基础的化疗方案对RRMM治疗有效,安全性较好。Objective To investigate the clinical efficacy and related adverse reactions of ixazomib-based chemotherapy regimens in the treatment of relapsed/refractory multiple myeloma(RRMM).Methods Twenty-one patients with RRMM who received≥2 courses of ixazomib-based chemotherapy regimens in Heze Municipal Hospital and Zoucheng People's Hospital of Shandong Province from October 2018 to February 2020 were collected.Among them,15 patients had previously received the bortezomib-based regimens,10 patients had received the lenalidomide-based regimens,and 6 patients had received the treatment regimens containing the above two drugs.The patients were treated by a two-drug or three-drug regimen:4 mg ixazomib was taken orally on day 1,8 and 15 in combination with other drugs(dexamethasone,cyclophosphamide or lenalidomide).The therapeutic efficacy and safety were evaluated after the 2nd and the 4th treatment cycles.Results The overall response rate(ORR)of 21 patients with RRMM after 2 treatment cycles was 38.09%(8/21),including 6 cases of partial remission(PR)and 2 cases of very good partial remission(VGPR).After 4 cycles,ORR was 57.14%(12/21),including 7 cases of PR,4 cases of VGPR,and 1 case of complete remission(CR).The incidence of grade 3-4 adverse reactions of the ixazomib-based chemotherapy regimens was 23.81%(5/21).Hematological adverse reactions included neutropenia,thrombocytopenia and anemia,and other common adverse reactions included the digestive tract reactions,fatigue,hypokalemia,etc.,and the peripheral nerve adverse reactions were all grade 2 or below grade 2.Conclusion The ixazomib-based chemotherapy regimens are effective and safe in treating RRMM.

关 键 词：多发性骨髓瘤 复发 抗肿瘤联合化疗方案 治疗结果 伊沙佐米 

分 类 号：R733.3[医药卫生—肿瘤]